company background image
4RY logo

Akeso DB:4RY Stock Report

Last Price

€5.45

Market Cap

€4.6b

7D

-1.8%

1Y

17.5%

Updated

28 Mar, 2024

Data

Company Financials +

Akeso, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Akeso
Historical stock prices
Current Share PriceHK$5.45
52 Week HighHK$6.05
52 Week LowHK$3.62
Beta0.49
1 Month Change-0.91%
3 Month Changen/a
1 Year Change17.46%
3 Year Change-2.68%
5 Year Changen/a
Change since IPO66.34%

Recent News & Updates

Recent updates

Shareholder Returns

4RYDE BiotechsDE Market
7D-1.8%1.2%2.5%
1Y17.5%34.7%7.0%

Return vs Industry: 4RY underperformed the German Biotechs industry which returned 34.7% over the past year.

Return vs Market: 4RY exceeded the German Market which returned 7% over the past year.

Price Volatility

Is 4RY's price volatile compared to industry and market?
4RY volatility
4RY Average Weekly Movement8.4%
Biotechs Industry Average Movement5.7%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 4RY has not had significant price volatility in the past 3 months.

Volatility Over Time: 4RY's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20122,778Michelle Xiahttps://www.akesobio.com

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK105, a PD-1 monoclonal antibody to treat classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.

Akeso, Inc. Fundamentals Summary

How do Akeso's earnings and revenue compare to its market cap?
4RY fundamental statistics
Market cap€4.65b
Earnings (TTM)€260.16m
Revenue (TTM)€580.57m

17.9x

P/E Ratio

8.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4RY income statement (TTM)
RevenueCN¥4.53b
Cost of RevenueCN¥133.25m
Gross ProfitCN¥4.39b
Other ExpensesCN¥2.36b
EarningsCN¥2.03b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)2.41
Gross Margin97.06%
Net Profit Margin44.81%
Debt/Equity Ratio65.7%

How did 4RY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.